Article
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
Clinical colorectal cancer - 1 Dec 2012
Gajate Pablo, Sastre Javier, Bando Inmaculada, Alonso Teresa, Cillero Lourdes, Sanz Julian, Caldés Trinidad, Díaz-Rubio Eduardo
Abstract excerpt
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) with activating mutations at codon 12 or 13 of the KRAS gene are currently excluded from treatment with monoclonal antibodies against the epidermal growth factor receptor (EGFR), for example, cetuximab. Occasionally, some of these patients benefit from treatment with cetuximab, especially patients with a mutation at codon 13. We conducted an analysis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.